Diseases of the Colon & Rectum

, Volume 35, Issue 11, pp 1085–1088 | Cite as

Clinical trial of oral diosmin (Daflon®) in the treatment of hemorrhoids

  • Wuttichai Thanapongsathorn
  • Tanit Vajrabukka
Original Contributions


A double-blind, comparative, controlled study on the effectiveness of the addition of oral diosmin (Daflon®;Lab. Servier, Orléans, France) and placebo to a conservative regime of bulk laxative in the treatment of acute symptoms of first-degree and second-degree internal hemorrhoids was undertaken in 100 patients. The diosmin and placebo groups, with 50 patients each, were comparable in age, sex, symptoms, and the severity of the underlying hemorrhoids. During the first four days, the patients received 12 tablets in three divided doses, and then they received two tablets twice daily for another 10 days. Subjective and objective changes were assessed at the 4th and 14th days of treatment. The diosmin group showed statistically significant objective improvement (P<0.01) without accompanying subjective improvement on the fourth day. However, at day 14, there was no significant difference in either subjective or objective improvement between the two groups. Two cases in the placebo group were taken out of the trial on the fourth day owing to clinical deterioration. No side effect of diosmin was detected in this study.

Key words

Hemorrhoids Oral antihemorrhoid drugs Diosmin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Desnoyers P. General pharmacological review of Daflon. In: European symposium on venous disease and its treatment. Rome, April 1978. Selected papers published by Gazette Medicale de France, 1987: 17–21.Google Scholar
  2. 2.
    Kissel P, Royer R. Contribution au traitement de la maladie veineuse, Etude par la plethysmographie gazeuse d'un nouveau prineipe vaso-actif. Therapeutique 1970;46:907–9.PubMedGoogle Scholar
  3. 3.
    Klemn J. Clinical and pharmacological study of the venous action of Daflon using the clearance of xenon 133. Gazette Medicale de France 1976;83:3158–65.Google Scholar
  4. 4.
    Annoni F, Boccasanta P, Chiurazzi D, Mozzi E, Oberhauser V. Treatment of acute symptoms of hemorrhoid disease with high-dose oral 0-(beta-hydroxy-ethyl) rutosides. Minerva Med 1986;77:1663–8.PubMedGoogle Scholar
  5. 5.
    Thorp RH, Hughes ES. A clinical trial of trihydroxy-ethyl-rutoside (“VAREMOID”) in the treatment of hemorrhoid. Med J Aust 1970;2:1076–8.PubMedGoogle Scholar
  6. 6.
    Clyne MB, Freeling P, Ginsborg S. Troxerutin in the treatment of hemorrhoids. Practitioner 1967;198:420–3.PubMedGoogle Scholar
  7. 7.
    Goligher JC. Surgery of the anus, rectum and colon. 5th ed. London: Bailliere Tindall, 1984:101.Google Scholar
  8. 8.
    Thomson WS. The nature of haemorrhoids. Br J Surg 1975;62:542–52.PubMedGoogle Scholar
  9. 9.
    Webster DJ, Gough DC, Craven JL. The use of bulk evacuant in patients with haemorrhoids. Br J Surg 1978;65:291–2.PubMedGoogle Scholar
  10. 10.
    Moesgaard F, Nielsen ML, Hansen JB, Knudsen JT. High-fiber diet reduces bleeding and pain in patients with hemorrhoids. Dis Colon Rectum 1982;25:454–6.PubMedGoogle Scholar

Copyright information

© American Society of Colon and Rectal Surgeons 1992

Authors and Affiliations

  • Wuttichai Thanapongsathorn
    • 1
  • Tanit Vajrabukka
    • 1
  1. 1.Department of Surgery, Faculty of MedicineChulalongkorn UniversityBangkokThailand

Personalised recommendations